



JUN 14 2004

TECH CENTER 1524

SHEET 1 OF 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4220-78-PUS	SERIAL NO. 10/049,427
	APPLICANT THOR	
	FILING DATE May 6, 2002	GROUP ART 1617

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

GM	A1.	Hamilton et al., "Determination of dapoxetine, an investigational agent with the potential for treating depression, and its mono- and di-desmethyl metabolites in human plasma using column-switching high-performance liquid chromatography," <i>Journal of Chromatography</i> 1993, 612:253-261
GM	A2.	Waldinger et al., "Antidepressants and ejaculation: a double-blind, randomized, fixed-dose study with mirtazapine and paroxetine," <i>J. Clin Psychopharmacology</i> 2003, 23(5):467-470, Abstract only, from PubMed - PMID:14520123
GM	A3.	Kennedy et al., "Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine," <i>J. Clin Psychiatry</i> 2000, 61(4):276-281, Abstract only, from PubMed - PMID:10830148

EXAMINER <i>Gregory W. Mitchell</i>	DATE CONSIDERED <i>03/03/05</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	